U.K. Watchdog Says Vivisol Deal for Air Liquide's Home-Oxygen Business Could Reduce Competition
By Dominic Chopping
The U.K. antitrust watchdog said it could launch an in-depth merger probe into Vivisol's proposed acquisition of Air Liquide Healthcare's home-oxygen business, unless the companies address competition concerns.
The Competition and Markets Authority said Thursday that an initial investigation concluded that the deal might result in a substantial lessening of competition in the U.K.
Dolby Medical Home Respiratory Care, trading as Vivisol, has agreed to acquire the business assets of Air Liquide Healthcare used to supply home-oxygen services to U.K. National Health Service patients.
Vivisol is a subsidiary of Italy-listed Sol.
The CMA said both Vivisol and Air Liquide provide home-oxygen services to NHS patients and the two companies now have until Nov. 26 to offer remedies to its competition concerns. If no such remedies are offered, or the CMA decides that they are insufficient, the watchdog will refer the merger for an in-depth Phase 2 investigation.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
November 19, 2026 03:29 ET (08:29 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

The 10 Best Dividend Stocks

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

